Tirzepatide vs Semaglutide: Titration Speed Compared

GLP-1 · 2026-05-03

Both compounds require titration but at different speeds and different ladders. Here's a side-by-side comparison.

Why titration exists

GLP-1 (and GLP-1/GIP for tirzepatide) agonists slow gastric emptying. Going to a high dose immediately produces severe nausea, vomiting, and constipation in most people. Slow titration gives the GI tract time to adapt.

Side-by-side ladders

Week rangeSemaglutide doseTirzepatide dose
1–40.25 mg/week2.5 mg/week
5–80.5 mg/week5 mg/week
9–121.0 mg/week7.5 mg/week
13–161.7 mg/week10 mg/week
17–202.4 mg/week12.5 mg/week
21+2.4 mg (max)15 mg (max)

Time to max dose

Semaglutide: 17 weeks to maintenance (2.4 mg).

Tirzepatide: 21 weeks to max (15 mg).

Tirzepatide titration is one rung longer because there are more dose levels.

Side effect profiles

Both share GI side effects (nausea, fatigue, constipation, sulfur burps). Tirzepatide's GIP component appears to reduce nausea slightly compared to pure GLP-1, though individual variation dominates.

Weight loss expectations (clinical trial data)

CompoundAverage weight loss at max dose, 72 weeks
Semaglutide 2.4 mg (Wegovy STEP 1)~14.9% body weight
Tirzepatide 15 mg (SURMOUNT-1)~22.5% body weight

Tirzepatide produces meaningfully more weight loss on average. Individual response varies widely.

Hold + step-down patterns

Many users (with clinician input) deviate from the manufacturer schedule:

How Peptra tracks both

Both schedules are pre-loaded. You can advance manually or auto-advance with the manufacturer cadence. Weight is logged weekly with side-effect severity scored 0-3. The chart shows weight trajectory overlaid with dose changes — easy to see if a titration step is producing the expected response.

Join the Peptra waitlist →